Last $74.46 USD
Change Today -0.30 / -0.40%
Volume 70.3K
DVA On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 10:15 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

davita healthcare partners i (DVA) Snapshot

Open
$74.55
Previous Close
$74.76
Day High
$74.59
Day Low
$74.01
52 Week High
09/2/14 - $75.27
52 Week Low
11/6/13 - $52.75
Market Cap
16.0B
Average Volume 10 Days
884.5K
EPS TTM
$3.77
Shares Outstanding
214.8M
EX-Date
--
P/E TM
19.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for DAVITA HEALTHCARE PARTNERS I (DVA)

davita healthcare partners i (DVA) Related Businessweek News

View More BusinessWeek News

davita healthcare partners i (DVA) Details

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; ESRD clinical research programs; physician services; and direct primary care services. As of March 31, 2014, it operated 2,173 outpatient dialysis centers, including 2,098 centers located in the United States; and 75 centers located in 10 countries outside the United States. The company was formerly known as DaVita Inc. and changed its name to DaVita HealthCare Partners Inc. in November 2012. DaVita HealthCare Partners Inc. was founded in 1994 and is headquartered in Denver, Colorado.

57,400 Employees
Last Reported Date: 02/21/14
Founded in 1994

davita healthcare partners i (DVA) Top Compensated Officers

Co-Chairman, Chief Executive Officer and Chie...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $213.6K
Chief Executive Officer of Kidney Care Divisi...
Total Annual Compensation: $765.4K
Chief Accounting Officer
Total Annual Compensation: $650.0K
Chief Legal Officer
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

davita healthcare partners i (DVA) Key Developments

DaVita HealthCare Partners Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

DaVita HealthCare Partners Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total net revenue was $3,172.49 million against $2,871.67 million a year ago. Operating income was $484.29 million against $522.02 million a year ago. Income from continuing operations before income taxes was $282.31 million against $412.55 million a year ago. Income from continuing operations was $181.42 million or $0.68 diluted per share against $283.36 million or $1.18 diluted per share a year ago. Net income attributable to the company was $147.68 million or $0.68 diluted per share against $254.38 million or $1.18 diluted per share a year ago. Operating income excluding a contingent earn-out obligation adjustment was $484.3 million against $465 million a year ago. Operating cash flow was $262.4 million against $306.8 million a year ago. Capital expenditure: Routine maintenance/IT/other was $64.5 million against $58.3 million a year ago. Adjusted income from continuing operations attributable to the company was $205.72 million against $197.4 million a year ago. Adjusted income attributable to the company was $230.72 million against $221.55 million a year ago. Adjusted diluted income per share from continuing operations was $0.95 against $0.92 a year ago. Adjusted diluted income per share was $1.06 against $1.03 a year ago. Adjusted operating income was $484.29 million against $465.04 million a year ago. Adjusted income before income taxes attributable to the company was $248.2 million against $326.28 million a year ago. For the six months, the company reported total net revenue was $6,215.26 million against $5,701.26 million a year ago. Operating income was $925.52 million against $688.88 million a year ago. Income from continuing operations before income taxes was $618.9 million against $474.19 million a year ago. Income from continuing operations was $393.16 million or $1.53 diluted per share against $329.86 million or $1.26 diluted per share a year ago. Net income attributable to the company was $330.97 million or $1.53 diluted per share against $284.54 million or $1.33 diluted per share a year ago. Net cash provided by operating activities was $681.5 million against $686.03 million a year ago. Additions of property and equipment, net were $278.59 million against $686.03 million a year ago. Purchase of intangible assets and equity investment was $4.76 million against $7,000 a year ago. Operating income excluding a contingent earn-out obligation adjustment was $925.5 million. Adjusted income from continuing operations attributable to the company was $389.01 million against $394.31 million a year ago. Adjusted income attributable to the company was $438.83 million against $442.61 million a year ago. Adjusted diluted income per share from continuing operations was $1.80 against $1.84 a year ago. Adjusted diluted income per share was $2.03 against $2.06 a year ago. Adjusted operating income was $925.52 million against $931.9 million a year ago. Adjusted income before income taxes attributable to the company was $556.25 million. Capital expenditure: Routine maintenance/IT/other was $113.9 million. For the full year 2014, the company updates enterprise operating income guidance of $1.755 billion to $1.840 billion. This includes, number one, reducing the high end of HCP guidance so that the range is now $205 million to $240 million. This includes the onetime second quarter revenue benefits that Kent discussed earlier. And number two, increasing Kidney Care guidance of $1.55 billion to $1.60 billion. The company still expects operating cash flow to be between $1.45 billion and $1.55 billion in 2014, excluding any payments associated with the potential PRI settlement with the government. Effective tax rate attributable of 40% to 41% for the full year 2014.

Craig Samitt Steps Down from HealthCare Partners President and CEO, Effective August 1, 2014

DaVita HealthCare Partners Inc. announced that HealthCare Partners (HCP) president and CEO Dr. Craig Samitt is stepping down from HCP effective August 1, 2014. Kent Thiry, co-chairman and CEO of DaVita HealthCare Partners, will take over the role of CEO of HCP, working in tandem with the Office of Chief Medical Officer.

DaVita HealthCare Partners Inc. to Report Q2, 2014 Results on Jul 31, 2014

DaVita HealthCare Partners Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVA:US $74.46 USD -0.30

DVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fresenius Medical Care AG & Co KGaA €53.86 EUR -0.35
Fresenius SE & Co KGaA €38.37 EUR -0.11
View Industry Companies
 

Industry Analysis

DVA

Industry Average

Valuation DVA Industry Range
No financial data is available for DVA.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAVITA HEALTHCARE PARTNERS I, please visit www.davita.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.